AAAlifeiye Aikebaier

Alifeiye Aikebaier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alifeiye Aikebaier has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elucidating the multi-target pharmacological mechanism of Xiaoyandina for the treatment of hepatitis C virus based on bioinformatics and cyberpharmacology studies

    by Dilihuma Dilimulati, Nuerbiye Nueraihemaiti, Sendaer Hailati, Mengyuan Han, Kayisaier Abudurousuli, Nulibiya Maihemuti, Alhar Baishan, Alfira Aikebaier, Maidina Abulizi, Wenting Zhou

    An estimated 170 million people worldwide suffer from chronic hepatitis C virus (HCV) infection, which is the main reason for liver transplantation in numerous nations. Traditional Chinese medicine is also frequently employed in medicine to treat HCV. Xiaoyandina is frequently employed in traditional medicine, and which has traditionally been used to cure acute and chronic hepatitis, jaundice, acute and chronic cholecystitis, and acute and chronic cholangitis. The information related to active compounds was retrieved from public databases and through literature review which was later combined with differentially expressed genes obtained through microarray datasets; a compound–target genes–disease network was constructed which uncovered that Kaempferol, Sesamin, and Quercetin decisively contributed to the cell growth and proliferation by affecting STAT1, interleukin-6, and CXCL10 proteins. The molecular docking and molecular dynamics simulation of 50 ns well complemented the binding affinity of the compound and revealed strong stability of predicted compounds at the docked site. In total, compound targets were obtained separately from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. And 27, 10,894, 6, and 20 disease targets were acquired separately based on OMIM, GeneCard, DrugBank, and PharmGkb databases. Then, we constructed the compound–target network and protein–protein interaction network. Three hundred ninety-four differentially expressed genes were observed (231 up-regulated and 163 downregulated genes). Hub genes were screened through survival analysis, including interleukin-6, STAT1, and CXCL10. Finally, molecular docking and molecular dynamics analysis results showed more stable binding between 3 hub genes and the 2 most active compounds Kaempferol and Quercetin. Our research suggests a novel scientific approach for evaluating the multi-component, multi-target impact of XYDN’s active compounds. The present investigation suggested Quercetin, Kaempferol, and Sesamin as possible HCV treatments by combining bioinformatics techniques and network pharmacology. But the findings were not validated in actual patients, so further investigation is needed to confirm the potential use of XYDN towards HCV.


  • Open Access

    Searching for Hub Genes of Quince–Basil Co-Administration Against Atherosclerosis Using Bioinformatics Analysis and Experimental Validation

    by Sendaer Hailati, Meng-Yuan Han, Dilihuma Dilimulati, Nuerbiye Nueraihemaiti, Alhar Baishan, Alifeiye Aikebaier, Wen-Ting Zhou

    Background: Atherosclerosis (AS) has one of the highest rates of morbidity and death globally. Cydonia oblonga Mill. (quince, COM) and Ocimum basilicum L. (basil, OB) are Uyghur medicines that are often used for anti-inflammatory, anti-tumor, and cardiovascular disease treatment. This study aimed to uncover the hub genes of the quince-basil co-administration against AS and validate them. Methods: Network pharmacology analysis and bioinformatics analysis methods were utilized to map the network and obtain four hub genes. Experiments were performed in vivo and in vitro using HUVEC and zebrafish to validate the therapeutic effect of COM-OB co-administration against AS. Finally, the hub genes were validated by Western blot. Results: Screening by network pharmacology analysis and bioinformatics analysis obtained a total of 3302 drug targets, 1963 disease targets, and 1630 DEGs. A series of bioinformatic analyses were utilized to ultimately screen four hub genes, and the stability was also verified by molecular docking and molecular dynamics. COM-OB total flavonoids co-administration significantly decreased PA-induced lipid deposition in HUVEC and reduced high cholesterol-induced fat accumulation in zebrafish. Western blot results showed that COM-OB co-administration significantly affected the expression of hub genes. Conclusions: The study identified and validated four hub genes, COL1A1, COL3A1, BGLAP, and NOX4, thus providing a rationale for the treatment of AS with COM and OB co-administration.


  • Open Access

    Evaluation of the Efficacy of OSU-2S in the Treatment of Non-Small-Cell Lung Cancer and Screening of Potential Targets of Action

    by Mengyuan Han, Xiangran Liu, Sendaer Hailati, Nurbiya Nurahmat, Dilihuma Dilimulati, Alhar Baishan, Alifeiye Aikebaier, Wenting Zhou

    (1) Background: OSU-2S is a derivative of FTY720 and exhibits significant inhibitory effects on various cancer cells. There is currently no research on the mechanism of the impact of OSU-2S on NSCLC development. We analysed and validated the hub genes and pharmacodynamic effects of OSU-2S to treat NSCLC. (2) Methods: The hub genes of OSU-2S for the treatment of NSCLC were screened in PharmMapper, genecard, and KM Plotter database by survival and expression analysis. The effect of OSU-2S on hub gene expression was verified by Western blot analysis. The ex vivo and in vivo efficacy of OSU-2S on tumour growth was verified using A549 cells and a xenografted animal model. (3) Results: A total of 7 marker genes for OSU-2S treatment of NSCLC were obtained. AURKA and S1PR1 were screened as hub genes. Significant differences in the expression of AURKA and S1PR1 between normal and lung adenocarcinoma (LUAD) tissues were found in the GEPIA2 database; Western blot showed that OSU-2S could affect p-AURKA and S1PR1 protein expression. OSU-2S significantly inhibited tumour growth in A549 cells and xenografted animal models. (4) Conclusions: Our study confirms the inhibitory effect of OSU-2S on NSCLC, screens and demonstrates its potential targets AURKA(p-AURKA) and S1PR1, and provides a research basis for treating NSCLC with OSU-2S.